Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB092 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Panel 1: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Panel 2: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Panel 3: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Panel 4: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Name | Type | Description |
|---|---|---|
| BIIB092 | DRUG | See Arm Descriptions for dosing information. |
| Placebo | DRUG | See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available) |
Inclusion Criteria 1. Probable or possible PSP defined as: * at least a 12-month history of postural instability or falls during the first 3 years that symptoms are present * a decreased downward saccade velocity at screening defined as observable eye movement deviation from the "main sequen...
BIIB092 is an investigational small molecule being developed for the treatment of Progressive Supranuclear Palsy (PSP), a rare neurological disorder. It is administered intravenously and is currently in clinical development, having completed a Phase 1 trial. BIIB092 is not yet approved and remains under investigation for this condition.
BIIB092 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. Biogen is conducting clinical research on this investigational small molecule for Progressive Supranuclear Palsy, with the drug having completed a Phase 1 study.
BIIB092 is in Phase 1 of clinical development. It has completed a Phase 1 multiple ascending dose study in patients with Progressive Supranuclear Palsy. The drug is investigational and has not received FDA approval, as it remains in early-stage clinical testing.
BIIB092 has been studied in one completed clinical trial, identified as NCT02460094. This Phase 1 study was a multiple ascending dose trial of intravenously administered BIIB092 in patients with Progressive Supranuclear Palsy. The trial enrolled 48 participants in the United States and was randomized, double-blind, and controlled.
Yes, BIIB092 is also known as BMS-986168. The completed clinical trial NCT02460094 was titled as a study of BMS-986168 (BIIB092), confirming that these names refer to the same investigational drug. Both names are used interchangeably in clinical research documentation.